For rs12028023 in RAS protein activator‐like 2 (RASAL2), we studied its effect by MAPK pathway activation status (by comparing to 760 patients without MAPK‐activated CRCs), MAPK gene mutation status, surface area of the primary tumor (as a marker of proliferation), and expression on RASAL2. This evidence concerns the gene RASAL2 and neoplasm.